ABOS market overview

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.

Latest price: $2.34
Daily change: +0.00%
Market state: closed
As of: 2026-09-23 19:33:59 ET

The interactive chart loads with current market data when StockStorm starts.

Market information is provided for research and visualization and is not investment advice.